With over 22 years of experience, Dr. Diane Seimetz is a leading drug development and regulatory expert and an experienced entrepreneur and manager in the biopharmaceutical sector. Since 2013, the co-founder and former CEO of Biopharma Excellence (acquired by the Pharmalex group) has been advising clients on drug development and regulatory approval of novel therapies with the aim of making innovations available to patients early. Previously, Dr. Seimetz held a position as an Executive Vice President at Fresenius Health Care Group, being responsible for the international development of first-in-class biologic drugs. A doctoral pharmacist by trade, Dr. Seimetz is serving on the board of Directors at Humacyte and Cumulus Oncology. She is a member of several advisory boards and committees, including Temedica, the Helmholtz Validation Fund and the Aglaia Oncology Fund.